Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$4.99 – $5.77
67% from low
Exchange
OTC Link
ADRC
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $187.8M | $221.6M | $250.1M | $287.3M | $274.6M | $261.9M | $257.6M | $250.9M |
| Cost of revenue | $134.3M | $169.5M | $181.1M | $199.6M | $195.1M | $197.1M | $181.2M | $186.6M |
| Gross profit | $53.5M | $52.1M | $69.0M | $87.7M | $79.5M | $64.8M | $76.4M | $64.2M |
| Gross margin | 28.5% | 23.5% | 27.6% | 30.5% | 28.9% | 24.8% | 29.7% | 25.6% |
| R&D | $9.2M | $5.1M | $7.7M | $9.3M | $6.9M | $8.7M | $11.6M | $15.9M |
| Operating income | $15.7M | $19.1M | $32.5M | $48.2M | $40.0M | $25.4M | $28.2M | $10.7M |
| EBITDA | $34.9M | $36.1M | $52.6M | $65.4M | $54.7M | $39.9M | $47.3M | $33.8M |
| Net income | $9.0M | $14.4M | $25.2M | $40.0M | $29.2M | $13.1M | $16.0M | −$242.0K |
| Net margin | 4.8% | 6.5% | 10.1% | 13.9% | 10.6% | 5.0% | 6.2% | -0.1% |
| EPS (diluted) | 0.15 | 0.27 | 0.47 | 0.66 | 0.48 | 0.21 | 0.26 | -0.00 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $267M | $0.00 | $0.00–$0.00 | 0 |
| 2027 | $284M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
STRATEC SE UNSP/ADR
No one on the platform currently holds STSEY.
No tracked institution reports a position in STSEY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-25 | $0.1366 | 2026-07-16 |
| 2025-07-01 | $0.1407 | 2025-07-17 |
| 2024-05-20 | $0.1188 | 2024-06-06 |
No one on the platform has traded STSEY yet.
| $998M |
| — |
| MEDGFMedacta Group S.A. | $83.91 | +0.00% | $1.7B | — |
| NURPFNeuren Pharmaceuticals Limited | $9.27 | +0.00% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.